Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
Saurabh Chhabra(Medical College of Wisconsin), Betty K. Hamilton(Cleveland Clinic), Olle Ringdén(Karolinska Institutet), Leo F. Verdonck(Isala), Melhem Solh(Johns Hopkins Hospital), Luciano J. Costa(University of Alabama at Birmingham), Leslie Lehmann(Harvard University), Álvaro Urbano-Ispizúa(University of St.Gallen), Margaret L. MacMillan(University of Minnesota Medical Center), Gèrard Socié(Hôpital Saint-Louis), Robert J. Hayashi(Washington University in St. Louis), Brenda Cooper(University Hospitals Cleveland Medical Center), Robert K. Stuart(Memorial Sloan Kettering Cancer Center), Navneet S. Majhail(Sarah Cannon), Rodrigo Martino(Universitat Autònoma de Barcelona), John L. Wagner(Leipzig University), Ravi Vij(Washington University in St. Louis), Yoshihiro Inamoto, Amin M. Alousi(McGill University), Harry C. Schouten, Muna Qayed(Emory University), Peiman Hematti(UW Health University Hospital), Takanori Teshima(Hokkaido University Hospital), Shahrukh K. Hashmi(Mayo Clinic), Michael Hemmer(McGill University), Sachiko Seo(National Cancer Center Hospital East), Joseph H. Antin(Dana-Farber Cancer Institute), Mukta Arora(Fairview Health Services), Taiga Nishihori(Moffitt Cancer Center), Stephen R. Spellman(National Marrow Donor Program), Daniel R. Couriel(The University of Texas MD Anderson Cancer Center), Usama Gergis(Thomas Jefferson University Hospital), Hisham Abdel‐Azim(University of Southern California), Mahmoud Aljurf(King Faisal Specialist Hospital & Research Centre), Dennis Dong Hwan Kim(University Health Network), Ayman Saad(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Robert Peter Gale(Imperial College London), Bipin N. Savani(Vanderbilt University Medical Center), Ying Liu(Medical College of Wisconsin), Joseph A. Pidala(Moffitt Cancer Center), Rammurti T. Kamble(Baylor College of Medicine), Mark R. Litzow(Dana-Farber Cancer Institute), Jean‐Yves Cahn(Université Grenoble Alpes), Jean A. Yared(University of Maryland, Baltimore), David I. Marks(University Hospitals Bristol NHS Foundation Trust), Hélène Schoemans(KU Leuven)
Cited by 51
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
|Nature|2010|1.3k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k